Revised forecast
Fiscal year ending June 2027 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Although net sales are expected to decline following the withdrawal from the cosmetics business in China, operating profit is expected to increase, supported by the stable earnings power of existing businesses and a stronger earnings base resulting from structural reforms, even as the company invests in its healthcare platform business.
Business reorganization loss: ¥144.179 million; business-site consolidation loss: ¥8.267 million; loss on retirement of fixed assets: ¥0.133 million; impairment loss on investment securities: ¥1.351 million; total extraordinary losses: ¥153.932 million
| Item | Details |
|---|---|
| Net Sales | Not disclosed → ¥3,270 million（-15.5% (year-on-year change)） |
| Operating profit | Not disclosed → ¥300 million（8.8% (year-on-year change)） |
| Ordinary income | Not disclosed → ¥310 million（7.7% (year-on-year change)） |
| Profit attributable to owners of the parent | Not disclosed → ¥250 million（17.8% (year-on-year change)） |
| Net income per share | Not disclosed → 9.56 yen（17.8% (year-on-year change)） |
| Fiscal Period Covered | Fiscal year ending June 2027 |
| Period Covered | Full year |
| Previous-period results | Net sales: ¥3,871 million; operating profit: ¥275 million; ordinary profit: ¥287 million; net income attributable to owners of the parent: ¥212 million (fiscal year ended June 2026) |
| Reason for the revision | Although net sales are expected to decline following the withdrawal from the cosmetics business in China, operating profit is expected to increase, supported by the stable earnings power of existing businesses and a stronger earnings base resulting from structural reforms, even as the company invests in its healthcare platform business. |
| Details and amount of extraordinary loss | Business reorganization loss: ¥144.179 million; business-site consolidation loss: ¥8.267 million; loss on retirement of fixed assets: ¥0.133 million; impairment loss on investment securities: ¥1.351 million; total extraordinary losses: ¥153.932 million |
| Dividend forecast revision | Annual dividend of ¥10 is planned for the fiscal year ending June 2027 (whether the forecast was revised is not stated) |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.For the fiscal year ending June 2027, net sales are expected to decline as the company withdraws from its cosmetics business in China. Operating profit is expected to increase, however, supported by the stable earnings power of existing businesses and a stronger earnings base resulting from structural reforms. The company also cited more efficient advertising and sales promotion in its health supplements business, order and contract trends in its biological evaluation systems and healthcare support businesses, and sales of OEM products and fixed-cost reductions in functional materials development.